Literature DB >> 10096048

Myelopathy secondary to spinal epidural abscess: case reports and a review.

K S Yin1, C Wang, Y Lucero.   

Abstract

Spinal epidural abscess (SEA) is a rare disease with an unknown incidence rate. This paper will illustrate that early diagnosis and rehabilitation may result in improved outcomes for patients with neck or back pain presenting with neurological deficits. Three cases of SEA in individuals without the commonly acknowledged risk factors of intravenous drug abuse (IVDA), invasive procedures, or immunosuppression were seen at our institution during a 10-month period between October 1995 and July 1996. The patients presented with neck or thoracic back pain and progressive neurological deficits without a febrile illness. Predisposing factors were thought to be urinary tract infection with underlying untreated diabetes mellitus in the first case, a history of recurrent skin infection in the second, and alcoholism without a definite source of infection in the third. Leukocytosis, elevated sedimentation rate, and confirmatory findings reported on magnetic resonance imaging (MRI) led to the diagnosis of SEA in all three cases. Immediate surgical drainage and decompression followed by proper antibiotic treatment and early aggressive rehabilitation led to good functional outcomes. All the individuals became independent in activities of daily living, wheelchair mobility, and bowel and bladder management. Two eventually became ambulatory.

Entities:  

Mesh:

Year:  1998        PMID: 10096048     DOI: 10.1080/10790268.1998.11719543

Source DB:  PubMed          Journal:  J Spinal Cord Med        ISSN: 1079-0268            Impact factor:   1.985


  2 in total

1.  Spinal epidural abscess.

Authors:  Krishna Kumar; Gary Hunter
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

2.  Spinal epidural abscess associated with moxibustion-related infection of the finger.

Authors:  Kyung Whan Lee; Soo Jeong Han; Dong Jun Kim; Mee jin Lee
Journal:  J Spinal Cord Med       Date:  2008       Impact factor: 1.985

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.